Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer-Reference-Cited by-同舟云学术

Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

Published:2015-01 Issue:1 Volume:26 Page:141-148
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Yamada Y.,Higuchi K.,Nishikawa K.,Gotoh M.,Fuse N.,Sugimoto N.,Nishina T.,Amagai K.,Chin K.,Niwa Y.,Tsuji A.,Imamura H.,Tsuda M.,Yasui H.,Fujii H.,Yamaguchi K.,Yasui H.,Hironaka S.,Shimada K.,Miwa H.,Hamada C.,Hyodo I.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference16 articles.

1. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial;Waters;Br J Cancer,1999

2. Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group

3. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group;Van Cutsem;J Clin Oncol,2006

4. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial;Kang;Ann Oncol,2009

5. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie;Al-Batran;J Clin Oncol,2008

Cited by 443 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modified Banxiaxiexin decoction benefitted chemotherapy in treating gastric cancer by regulating multiple targets and pathways;Journal of Ethnopharmacology;2024-09

2. The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer;Cancers;2024-08-26

3. An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma;Frontiers in Immunology;2024-08-26

4. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group;Japanese Journal of Clinical Oncology;2024-08-24

5. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial;Gastric Cancer;2024-08-20